VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESPRNewsWire • 04/23/24
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 04/22/24
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right NowThe Motley Fool • 04/22/24
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic PainBusiness Wire • 04/18/24
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolioMarket Watch • 04/11/24
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to WatchInvestopedia • 04/11/24
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech dealGeekWire • 04/11/24
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealInvestors Business Daily • 04/10/24